A Phase 1/2 interventional study of Nivolumab and Brentuximab Vedotin in Non-Hodgkin's Disease, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 6 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-03-07.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab+Brentuximab Vedotin dose as specified
Biological: Nivolumab · Drug: Brentuximab Vedotin
Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase
DLTs are defined as any study drug-related toxicity (brentuximab vedotin or nivolumab) that requires either a dose reduction or delay of more than 7 days of either study drug in Cycle 2 or delays the Cycle 3 Day 1 administration of combined treatment by more than 7 days.
Time frame: From first dose of treatment to 6 weeks after first dose
Safety Analysis - Number of Participant Deaths
Number of participant Deaths
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Safety Analysis - Number of Participants With Adverse Advents
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Safety Analysis - Number of Participants With Serious Adverse Events
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * requires inpatient hospitalization or causes prolongation of existing hospitalization. * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation
Number of participants with adverse events leading to discontinuation
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Safety Analysis - Number of Participants With Adverse Events Leading to Dose Delay or Reduction
Number of participants with adverse events leading to dose delay or reduction
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Safety Analysis - Number of Participants With Drug Related Adverse Events
Number of participants with Drug Related Adverse Events
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Safety Analysis - Percentage of Participants With Thyroid Test Abnormalities
Percentage of participants with specific thyroid test abnormalities
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Safety Analysis - Percentage of Participants With Liver Test Abnormalities
Percentage of participants with specific Liver test abnormalities
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Objective Response Rate (ORR)
The percentage of participants with a best overall response (BOR) of CR or PR. DLBCL, PTCL, PMBL \& MGZL complete and partial response are outlined in the Lugano Classification 2014 and Lymphoma Response to Immunomodulatory therapy Criteria. CTCL complete and partial response are defined in The consensus Global Response Score assessment.
Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Duration of Response (DOR)
DOR will be calculated from the date of initial documentation of a response (CR, or PR) to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever occurs first. DLBCL, PTCL, PMBL \& MGZL complete and partial response are outlined in the Lugano Classification 2014 and Lymphoma Response to Immunomodulatory therapy Criteria. CTCL complete and partial response are defined in The consensus Global Response Score assessment.
Time frame: From the first patient first visit to 8 months after the last patient first visit (up to 48 months)
Complete Response Rate (CRR)
The CRR is defined as the percentage of participants with a BOR (Best overall response) of CR divided by the number of treated participants. DLBCL, PTCL, PMBL \& MGZL (CR) 1.Complete disappearance of all detectable clinical evidence of disease. 2.Bone marrow: No evidence of FDG- avid disease in marrow. CTCL (CR) 1. 100% clearance of skin lesions. 2. all lymph nodes ≤1.5 cm, N3 classification and ≤ 1.5 cm in their long axis and \> 1 cm in their short axis at baseline, must be ≤ 1 cm in their short axis or biopsy negative for lymphoma. 3. organs should not be enlarged on examination or imaging 4. absence of blood involvement
Time frame: From first dose to the date of initial objectively documented progression or the date of subsequent therapy, whichever occurs first (up to 48 months)
Duration of Complete Response
The duration of CR will only be evaluated in participants with BOR of CR and is defined as the time from first documentation of CR to the date of relapse or death due to any cause, whichever occurs first. DLBCL, PTCL, PMBL \& MGZL (CR) 1.Complete disappearance of all detectable clinical evidence of disease. 2.Bone marrow: No evidence of FDG- avid disease in marrow. CTCL (CR) 1. 100% clearance of skin lesions. 2. all lymph nodes ≤1.5 cm, N3 classification and ≤ 1.5 cm in their long axis and \> 1 cm in their short axis at baseline, must be ≤ 1 cm in their short axis or biopsy negative for lymphoma. 3. organs should not be enlarged on examination or imaging 4. absence of blood involvement
Time frame: From first dose to the date of relapse or death due to any cause, whichever occurs first. (about 48 months)
Progression Free Survival (PFS)
PFS is defined as the time from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever comes first. Participants who are progression-free and alive or have unknown status will be censored at the last tumor assessment. Participants who did not have any onstudy tumor assessments and did not die will be censored on the date of first treatment. For participants who received subsequent therapy prior to documented progression, it will be censored on the last tumor assessment date prior to or on subsequent therapy.
Time frame: From first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever comes first. (about 48 months)
Overall Survival (OS)
OS is defined as the time from the date of first dose of study drug until the date of death (any reason). If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant was last known to be alive.
Time frame: From the first patient first visit to 8 months after the last patient first visit (about 48 months)
| Milestone | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Started | 42 | 33 | 29 | 10 | 30 |
| Phase 1 dlt evaluable participants | 2 | 1 | 3 | 0 | 0 |
| Completed phase 1 dlt evaluation | 2 | 1 | 3 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 42 | 33 | 29 | 10 | 30 |
| Withdrew: Disease progression | 29 | 19 | 13 | 5 | 8 |
| Withdrew: Study drug toxicity | 4 | 6 | 7 | 0 | 3 |
| Withdrew: Ae unrelated to study drug | 3 | 1 | 1 | 0 | 2 |
| Withdrew: Request to discontinue | 1 | 0 | 3 | 0 | 1 |
| Withdrew: Participant withdrew consent | 3 | 0 | 1 | 0 | 0 |
| Withdrew: Maximum clinical benefit | 1 | 7 | 1 | 3 | 13 |
| Withdrew: Other reasons | 1 | 0 | 2 | 2 | 3 |
| Withdrew: Poor/non-compliance | 0 | 0 | 1 | 0 | 0 |
DLTs are defined as any study drug-related toxicity (brentuximab vedotin or nivolumab) that requires either a dose reduction or delay of more than 7 days of either study drug in Cycle 2 or delays the Cycle 3 Day 1 administration of combined treatment by more than 7 days.
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase | 0 | 0 | 0 | — | — |
Number of participant Deaths
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participant Deaths | 24 | 22 | 3 | 3 | 5 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Adverse Advents | 42 | 33 | 29 | 10 | 30 |
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * requires inpatient hospitalization or causes prolongation of existing hospitalization. * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Serious Adverse Events | 22 | 19 | 14 | 4 | 10 |
Number of participants with adverse events leading to discontinuation
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation | 11 | 10 | 6 | 2 | 8 |
Number of participants with adverse events leading to dose delay or reduction
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Adverse Events Leading to Dose Delay or Reduction | 16 | 15 | 14 | 3 | 17 |
Number of participants with Drug Related Adverse Events
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Drug Related Adverse Events | 35 | 27 | 25 | 9 | 25 |
Percentage of participants with specific thyroid test abnormalities
| Percentage of Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| TSH > ULN | 34.6 | 29.6 | 18.2 | 11.1 | 24.0 |
| TSH > ULN w/ TSH ≤ ULN at baseline | 26.9 | 22.2 | 18.2 | 0 | 8.0 |
| TSH > ULN w/at least 1 FT3/FT4 value < LLN | 11.5 | 11.1 | 13.6 | 0 | 4.0 |
| TSH > ULN w/all other FT3/FT4 values ≥ LLN | 15.4 | 11.1 | 0 | 11.1 | 8.0 |
| TSH > ULN with FT3/FT4 testing missing | 7.7 | 7.4 | 4.5 | 0 | 12.0 |
| TSH < LLN | 7.7 | 7.4 | 4.5 | 11.1 | 24.0 |
| TSH < LLN w/TSH ≥ LLN at baseline | 7.7 | 0 | 4.5 | 0 | 20.0 |
| TSH < LLN w/at least 1 FT3/FT4 value > ULN | 0 | 3.7 | 4.5 | 0 | 20.0 |
| TSH < LLN w/ all other FT3/FT4 values ≤ ULN | 0 | 3.7 | 0 | 11.1 | 0 |
| TSH < LLN w/ FT3/FT4 test missing | 7.7 | 0 | 0 | 0 | 4.0 |
Percentage of participants with specific Liver test abnormalities
| Percentage of Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| ALT or AST > 3 x ULN | 4.8 | 6.1 | 13.8 | 20.0 | 24.0 |
| ALT or AST > 5 x ULN | 2.4 | 0 | 6.9 | 10.0 | 10.0 |
| ALT or AST > 10 x ULN | 0 | 0 | 0 | 10.0 | 6.7 |
| ALT or AST > 20 x ULN | 0 | 0 | 0 | 10.0 | 6.7 |
| Total Bilirubin > 2 x ULN | 0 | 6.1 | 3.4 | 20.0 | 3.3 |
| ALT or AST elevation > 3 x ULN w/Bilirubin > 2 x ULN within 1 day | 0 | 3.0 | 3.4 | 10.0 | 3.3 |
| ALT or AST elevation > 3 x ULN w/Bilirubin 2 x ULN within 30 days | 0 | 3.0 | 3.4 | 10.0 | 3.3 |
The percentage of participants with a best overall response (BOR) of CR or PR. DLBCL, PTCL, PMBL \& MGZL complete and partial response are outlined in the Lugano Classification 2014 and Lymphoma Response to Immunomodulatory therapy Criteria. CTCL complete and partial response are defined in The consensus Global Response Score assessment.
| Percentage of participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 28.6 (19.4 to 39.4) | 45.5 (33.3 to 58.0) | 41.4 (28.8 to 55.0) | 70.0 (44.8 to 88.4) | 73.3 (60.3 to 83.8) |
DOR will be calculated from the date of initial documentation of a response (CR, or PR) to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever occurs first. DLBCL, PTCL, PMBL \& MGZL complete and partial response are outlined in the Lugano Classification 2014 and Lymphoma Response to Immunomodulatory therapy Criteria. CTCL complete and partial response are defined in The consensus Global Response Score assessment.
| Months | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Duration of Response (DOR) | 3.55 (1.18 to 36.53) | 4.60 (2.76 to 12.75) | 26.97 (2.79 to NA) | 20.76 (1.22 to NA) | NA (23.33 to NA) |
The CRR is defined as the percentage of participants with a BOR (Best overall response) of CR divided by the number of treated participants. DLBCL, PTCL, PMBL \& MGZL (CR) 1.Complete disappearance of all detectable clinical evidence of disease. 2.Bone marrow: No evidence of FDG- avid disease in marrow. CTCL (CR) 1. 100% clearance of skin lesions. 2. all lymph nodes ≤1.5 cm, N3 classification and ≤ 1.5 cm in their long axis and \> 1 cm in their short axis at baseline, must be ≤ 1 cm in their short axis or biopsy negative for lymphoma. 3. organs should not be enlarged on examination or imaging 4. absence of blood involvement
| Percentage of Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Complete Response Rate (CRR) | 7.1 | 33.3 | 3.4 | 50.0 | 40.0 |
The duration of CR will only be evaluated in participants with BOR of CR and is defined as the time from first documentation of CR to the date of relapse or death due to any cause, whichever occurs first. DLBCL, PTCL, PMBL \& MGZL (CR) 1.Complete disappearance of all detectable clinical evidence of disease. 2.Bone marrow: No evidence of FDG- avid disease in marrow. CTCL (CR) 1. 100% clearance of skin lesions. 2. all lymph nodes ≤1.5 cm, N3 classification and ≤ 1.5 cm in their long axis and \> 1 cm in their short axis at baseline, must be ≤ 1 cm in their short axis or biopsy negative for lymphoma. 3. organs should not be enlarged on examination or imaging 4. absence of blood involvement
| Months | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Duration of Complete Response | 36.53 (9.92 to NA) | 7.39 (2.17 to NA) | NA (NA to NA) | NA (NA to NA) | NA (27.89 to NA) |
PFS is defined as the time from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever comes first. Participants who are progression-free and alive or have unknown status will be censored at the last tumor assessment. Participants who did not have any onstudy tumor assessments and did not die will be censored on the date of first treatment. For participants who received subsequent therapy prior to documented progression, it will be censored on the last tumor assessment date prior to or on subsequent therapy.
| Months | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 2.60 (1.38 to 2.79) | 4.30 (1.58 to 5.62) | 15.61 (4.86 to NA) | 21.88 (0.07 to NA) | 25.95 (2.63 to NA) |
OS is defined as the time from the date of first dose of study drug until the date of death (any reason). If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant was last known to be alive.
| Months | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Overall Survival (OS) | 13.31 (6.57 to 15.87) | 11.07 (5.16 to 15.31) | 37.16 (18.63 to NA) | NA (0.07 to NA) | NA (NA to NA) |
Number of participant Deaths This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participant Deaths - Extended Collection | 30 | 26 | 14 | 4 | 8 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Adverse Events - Extended Collection | 42 | 33 | 29 | 10 | 30 |
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * requires inpatient hospitalization or causes prolongation of existing hospitalization. * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Serious Adverse Events - Extended Collection | 22 | 19 | 14 | 4 | 10 |
Number of Adverse events leading to discontinuation This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation - Extended Collection | 12 | 11 | 10 | 2 | 9 |
Number of Drug Related Adverse Events This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)
| Participants | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) |
|---|---|---|---|---|---|
| Safety Analysis - Number of Participants With Drug Related Adverse Events - Extended Collection | 35 | 28 | 26 | 9 | 25 |
Collected over From first patient first visit to first to final data base lock. Approximately 6 years and 7 months. All cause mortality is calculated from first treatment to final data base lock.. Approximately 6 years and 7 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DLBCL | 30/42 (71.4%) | 23/42 (54.8%) | 42/42 (100%) |
| PTCL | 26/33 (78.8%) | 25/33 (75.8%) | 33/33 (100%) |
| CTCL | 14/29 (48.3%) | 18/29 (62.1%) | 28/29 (96.6%) |
| MGZL | 4/10 (40%) | 5/10 (50%) | 9/10 (90%) |
| PMBL | 8/30 (26.7%) | 12/30 (40%) | 28/30 (93.3%) |
| Event | DLBCL | PTCL | CTCL | MGZL | PMBL |
|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 13/42 | 9/33 | 4/29 | 1/10 | 2/30 |
| PyrexiaGeneral disorders | 0/42 | 10/33 | 2/29 | 1/10 | 2/30 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/42 | 1/33 | 0/29 | 1/10 | 2/30 |
| General physical health deteriorationGeneral disorders | 1/42 | 0/33 | 0/29 | 1/10 | 0/30 |
| PainGeneral disorders | 0/42 | 0/33 | 0/29 | 1/10 | 0/30 |
| ParaparesisNervous system disorders | 0/42 | 0/33 | 0/29 | 1/10 | 0/30 |
| PneumoniaInfections and infestations | 4/42 | 2/33 | 1/29 | 0/10 | 1/30 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/42 | 1/33 | 2/29 | 0/10 | 0/30 |
| Acute kidney injuryRenal and urinary disorders | 0/42 | 2/33 | 0/29 | 0/10 | 2/30 |
| Small intestinal obstructionGastrointestinal disorders | 0/42 | 2/33 | 0/29 | 0/10 | 0/30 |
| Event | DLBCL | PTCL | CTCL | MGZL | PMBL |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/42 | 10/33 | 1/29 | 6/10 | 3/30 |
| DiarrhoeaGastrointestinal disorders | 20/42 | 14/33 | 15/29 | 0/10 | 4/30 |
| PyrexiaGeneral disorders | 13/42 | 12/33 | 14/29 | 2/10 | 7/30 |
| FatigueGeneral disorders | 16/42 | 15/33 | 8/29 | 1/10 | 2/30 |
| NeutropeniaBlood and lymphatic system disorders | 8/42 | 9/33 | 0/29 | 4/10 | 13/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/42 | 9/33 | 6/29 | 3/10 | 13/30 |
| NauseaGastrointestinal disorders | 17/42 | 12/33 | 10/29 | 0/10 | 5/30 |
| Neuropathy peripheralNervous system disorders | 14/42 | 5/33 | 9/29 | 0/10 | 9/30 |
| PruritusSkin and subcutaneous tissue disorders | 3/42 | 10/33 | 8/29 | 1/10 | 4/30 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/42 | 8/33 | 1/29 | 3/10 | 5/30 |
| Age, Continuous(Years) | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) | Total |
|---|---|---|---|---|---|---|
| Mean | 57.7 ± 13.2 | 59.1 ± 12.0 | 57.9 ± 12.39 | 39.9 ± 15.2 | 37.3 ± 12.9 | 52.6 ± 15.6 |
| Sex: Female, Male(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) | Total |
|---|---|---|---|---|---|---|
| Female | 20 | 11 | 13 | 4 | 17 | 65 |
| Male | 22 | 22 | 16 | 6 | 13 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 0 | 1 | 4 |
| Not Hispanic or Latino | 14 | 13 | 16 | 6 | 9 | 58 |
| Unknown or Not Reported | 27 | 18 | 13 | 4 | 20 | 82 |
| Race (NIH/OMB)(Participants) | Diffuse Large B-cell Lymphoma (DLBCL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-cell Lymphoma (CTCL) | Mediastinal Grey Zone Lymphoma (MGZL) | Primary Mediastinal B-cell Lymphoma (PMBL) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 0 | 0 | 0 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 | 1 | 2 | 13 |
| White | 36 | 30 | 24 | 9 | 26 | 125 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2016 to primary completion in Jan 2020, 47 months.
Results were first posted in Mar 2023, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Brentuximab Vedotin